DE10110747A1
(en)
*
|
2001-03-07 |
2002-09-12 |
Bayer Ag |
Substituted 2,6-diamino-3,5-dicyano-4-aryl-pyridines and their use
|
AU2003291342A1
(en)
*
|
2002-11-05 |
2004-06-07 |
Arena Pharmaceuticals, Inc. |
Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
|
CN1805939B
(en)
*
|
2003-06-17 |
2010-10-13 |
艾尼纳制药公司 |
Benzazepine derivatives useful for the treatment of 5HT2C receptor associated diseases
|
US20070179155A1
(en)
*
|
2003-06-20 |
2007-08-02 |
Brian Smith |
N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases
|
PE20050483A1
(en)
|
2003-10-31 |
2005-08-25 |
Arena Pharm Inc |
TETRAZOLE DERIVATIVES OF FORMULA (I), ITS PHARMACEUTICAL COMPOSITIONS AND PROCESSES TO PRODUCE PHARMACEUTICAL COMPOSITIONS
|
DE10351903A1
(en)
*
|
2003-11-06 |
2005-06-09 |
Bayer Healthcare Ag |
New combination
|
DE102004042607A1
(en)
*
|
2004-09-03 |
2006-03-09 |
Bayer Healthcare Ag |
Substituted phenylaminothiazoles and their use
|
CA2583073A1
(en)
*
|
2004-10-05 |
2006-04-13 |
Bayer Healthcare Ag |
A guanylane cyclase stimulator and nitric oxide for treating bronchoconstriction and pulmonary vasoconstriction
|
EP2322162A1
(en)
*
|
2004-12-23 |
2011-05-18 |
Arena Pharmaceuticals, Inc. |
5HT2C receptor modulator compositions and methods of use
|
DE102005031576A1
(en)
*
|
2005-07-06 |
2007-01-25 |
Bayer Healthcare Ag |
Use of benzoic acid, pyrimidine and benzamide compounds, as activators of soluble guanylate cyclase for the treatment or prevention of reperfusion injury,
|
DE102005031575A1
(en)
|
2005-07-06 |
2007-01-11 |
Bayer Healthcare Ag |
Use of soluble guanylate cyclase activators to promote wound healing
|
DE102005047945A1
(en)
*
|
2005-07-16 |
2007-01-18 |
Bayer Healthcare Ag |
Use of soluble guanylate cyclase activators for the treatment of Raynaud's phenomena
|
DE102005047946A1
(en)
*
|
2005-10-06 |
2007-05-03 |
Bayer Healthcare Ag |
Use of soluble guanylate cyclase activators for the treatment of acute and chronic lung diseases
|
DE102006042143A1
(en)
*
|
2006-09-08 |
2008-03-27 |
Bayer Healthcare Aktiengesellschaft |
Novel substituted bipyridine derivatives and their use
|
DE102006043443A1
(en)
*
|
2006-09-15 |
2008-03-27 |
Bayer Healthcare Ag |
Novel aza-bicyclic compounds and their use
|
DE102006044696A1
(en)
*
|
2006-09-22 |
2008-03-27 |
Bayer Healthcare Ag |
3-cyano-5-thiazaheteroaryl-dihydropyridines and their use
|
DE102006054757A1
(en)
*
|
2006-11-21 |
2008-05-29 |
Bayer Healthcare Ag |
Novel aza-bicyclic compounds and their use
|
DE102006056740A1
(en)
*
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Cyclic substituted 3,5-dicyano-2-thiopyridines and their use
|
DE102006056739A1
(en)
*
|
2006-12-01 |
2008-06-05 |
Bayer Healthcare Ag |
Substituted 4-amino-3,5-dicyano-2-thiopyridines and their use
|
DE102007009494A1
(en)
|
2007-02-27 |
2008-08-28 |
Bayer Healthcare Ag |
New 1,6-naphthyridine or 8-azaquinazoline derivatives useful for treating aldosteronism, hypertension, cardiac insufficiency, myocardial infarct sequelae, liver cirrhosis, renal insufficiency and stroke
|
DE102007015034A1
(en)
|
2007-03-29 |
2008-10-02 |
Bayer Healthcare Ag |
Lactam-substituted dicarboxylic acids and their use
|
DE102007015035A1
(en)
|
2007-03-29 |
2008-10-02 |
Bayer Healthcare Ag |
Substituted dibenzoic acid derivatives and their use
|
DE102007019690A1
(en)
|
2007-04-26 |
2008-10-30 |
Bayer Healthcare Ag |
Use of cyclic substituted furopyrimidine derivatives for the treatment of pulmonary arterial hypertension
|
DE102007019691A1
(en)
|
2007-04-26 |
2008-10-30 |
Bayer Healthcare Ag |
Use of acyclically substituted furopyrimidine derivatives for the treatment of pulmonary arterial hypertension
|
RU2009145935A
(en)
*
|
2007-05-12 |
2011-06-20 |
Байер Шеринг Фарма Акциенгезельшафт (DE) |
RHC STIMULANTS, RHC ACTIVATORS AND COMBINATIONS FOR THE TREATMENT OF UROLOGICAL DISORDERS
|
DE102007026392A1
(en)
|
2007-06-06 |
2008-12-11 |
Bayer Healthcare Ag |
Solutions for the perfusion and preservation of organs and tissues
|
DE102007027799A1
(en)
|
2007-06-16 |
2008-12-18 |
Bayer Healthcare Ag |
Substituted furopyrimidines and their use
|
DE102007027800A1
(en)
|
2007-06-16 |
2008-12-18 |
Bayer Healthcare Ag |
Substituted bicyclic heteroaryl compounds and their use
|
DE102007035367A1
(en)
|
2007-07-27 |
2009-01-29 |
Bayer Healthcare Ag |
Substituted aryloxazoles and their use
|
DE102007036076A1
(en)
|
2007-08-01 |
2009-02-05 |
Bayer Healthcare Aktiengesellschaft |
Dipeptoid Produgs and their use
|
DE102007042754A1
(en)
|
2007-09-07 |
2009-03-12 |
Bayer Healthcare Ag |
Substituted 6-phenyl-nicotinic acids and their use
|
DE102007051762A1
(en)
|
2007-10-30 |
2009-05-07 |
Bayer Healthcare Ag |
Substituted pyrrolotriazines and their use
|
DE102007054786A1
(en)
|
2007-11-16 |
2009-05-20 |
Bayer Healthcare Ag |
Trisubstituted Furopyrimidines and their Use
|
DE102007061756A1
(en)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituted 4-aminopyrimidine-5-carboxylic acids and their use
|
DE102007061763A1
(en)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituted azabicyclic compounds and their use
|
DE102008022521A1
(en)
|
2008-05-07 |
2009-11-12 |
Bayer Schering Pharma Aktiengesellschaft |
1,4-Diaryl-pyrimidopyridazine-2,5-diones and their use
|
DE102008052013A1
(en)
|
2008-10-17 |
2010-04-22 |
Bayer Schering Pharma Aktiengesellschaft |
New 4-(4-cyano-2-thioaryl)dihydropyrimidinone compounds are neutrophil elastase inhibitors useful to treat or prevent e.g. pulmonary arterial hypertension, chronic obstructive pulmonary disease, acute lung injury, or cystic fibrosis
|
DE102007061757A1
(en)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Substituted 2-phenylpyrimidine-5-carboxylic acids and their use
|
DE102007061766A1
(en)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
New 4-(4-cyano-2-thioaryl)-dihydro-pyrimidinone compounds are human neutrophil elastase inhibitor, useful for the treatment or prevention of e.g. pulmonary arterial hypertonia, acute lung injury and diseases of the cardiovascular system
|
DE102007061764A1
(en)
|
2007-12-20 |
2009-06-25 |
Bayer Healthcare Ag |
Anellated cyanopyridines and their use
|
DE102008007400A1
(en)
|
2008-02-04 |
2009-08-06 |
Bayer Healthcare Ag |
Substituted furans and their use
|
US8822727B2
(en)
*
|
2008-03-04 |
2014-09-02 |
Arena Pharmaceuticals, Inc. |
Processes for the preparation of intermediates related to the 5-HT2C agonist (R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine
|
DE102008013587A1
(en)
*
|
2008-03-11 |
2009-09-17 |
Bayer Schering Pharma Aktiengesellschaft |
Heteroaryl-substituted dicyanopyridines and their use
|
DE102008018675A1
(en)
|
2008-04-14 |
2009-10-15 |
Bayer Schering Pharma Aktiengesellschaft |
Oxo-heterocyclic substituted carboxylic acid derivatives and their use
|
US20110092500A1
(en)
*
|
2008-05-10 |
2011-04-21 |
Bayer Schering Pharma Aktiengesellschaft |
Sgc stimulators, sgc activators and combinations thereof for the treatment of hearing impairment
|
EP2297104B1
(en)
*
|
2008-05-29 |
2013-08-07 |
Bayer Intellectual Property GmbH |
2-alkoxy-substituted dicyanopyridines and use thereof
|
DE102008030207A1
(en)
|
2008-06-25 |
2009-12-31 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted 7-sulfanylmethyl, 7-sulfinylmethyl and 7-sulfonylmethyl-indoles and their use
|
DE102008030206A1
(en)
|
2008-06-25 |
2009-12-31 |
Bayer Schering Pharma Aktiengesellschaft |
3-cyanoalky- and 3-hydroxyalkyl-indoles and their use
|
DE102008039083A1
(en)
|
2008-08-21 |
2010-02-25 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted 5-aminopyrazoles and their use
|
DE102008039082A1
(en)
|
2008-08-21 |
2010-02-25 |
Bayer Schering Pharma Aktiengesellschaft |
Azabicyclic-substituted 5-aminopyrazoles and their use
|
DE102008054205A1
(en)
*
|
2008-10-31 |
2010-05-06 |
Bayer Schering Pharma Aktiengesellschaft |
Use of helium-oxygen gas mixtures for the treatment of pulmonary arterial hypertension
|
WO2010065275A1
(en)
*
|
2008-11-25 |
2010-06-10 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
DE102008060967A1
(en)
|
2008-12-06 |
2010-06-10 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted phenylsulfonyltriazolones and their use
|
DE102008062567A1
(en)
|
2008-12-16 |
2010-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Dipeptoid prodrugs and their use
|
DE102008062566A1
(en)
|
2008-12-16 |
2010-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Amino acid ester prodrugs and their use
|
DE102008063992A1
(en)
|
2008-12-19 |
2010-09-02 |
Lerner, Zinoviy, Dipl.-Ing. |
New aliphatic substituted pyrazolopyridines and their use
|
DE102009004245A1
(en)
|
2009-01-09 |
2010-07-15 |
Bayer Schering Pharma Aktiengesellschaft |
Novel fused, heteroatom-bridged pyrazole and imidazole derivatives and their use
|
DE102009004197A1
(en)
|
2009-01-09 |
2010-07-15 |
Bayer Schering Pharma Aktiengesellschaft |
Heterocyclic fused diaryldihydropyrimidine derivatives and their use
|
WO2010081647A2
(en)
*
|
2009-01-17 |
2010-07-22 |
Bayer Schering Pharma Aktiengesellschaft |
Sgc stimulators of sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
|
DE102009006602A1
(en)
|
2009-01-29 |
2010-08-05 |
Bayer Schering Pharma Aktiengesellschaft |
Alkylamino-substituted dicyanopyridines and their amino acid ester prodrugs
|
DE102009012314A1
(en)
|
2009-03-09 |
2010-09-16 |
Bayer Schering Pharma Aktiengesellschaft |
Oxo-heterocyclic substituted alkylcarboxylic acids and their use
|
DE102009013642A1
(en)
|
2009-03-18 |
2010-09-23 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted phenylalanine derivatives and their use
|
DE102010001064A1
(en)
|
2009-03-18 |
2010-09-23 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use
|
DE102009016553A1
(en)
|
2009-04-06 |
2010-10-07 |
Bayer Schering Pharma Aktiengesellschaft |
Sulfonamide- and sulfoximine-substituted diaryldihydropyrimidinones and their use
|
DE102009028929A1
(en)
|
2009-08-27 |
2011-07-07 |
Bayer Schering Pharma Aktiengesellschaft, 13353 |
Heterocyclic-substituted 2-acetamido-5-aryl-1,2,4-triazolones and their use
|
US9260424B2
(en)
*
|
2009-10-26 |
2016-02-16 |
Auspex Pharmaceuticals, Inc. |
4,6-diaminopyrimidine stimulators of soluble guanylate cyclase
|
DE102009046115A1
(en)
|
2009-10-28 |
2011-09-08 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted 3-phenylpropanoic acids and their use
|
PE20180203A1
(en)
*
|
2009-11-27 |
2018-01-31 |
Adverio Pharma Gmbh |
PROCEDURE FOR THE PREPARATION OF {4,6-DIAMINE-2- [1- (2-FLUOROBENZYL) -1H-PIRAZOLO [3,4-B] PYRIDIN-3-IL] PYRIMIDIN-5-IL} METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE
|
UY33040A
(en)
*
|
2009-11-27 |
2011-06-30 |
Bayer Schering Pahrma Akitengesellschaft |
NEW FORMS POLYMORPHES OF {4,6DIAMINO-2- [1- (2-FLUOROBENCIL-1H-PIRAZOL [3,4-B] PIRIDIN-3-IL] PIRIMIDIN-5-IL} METHYL CARBAMATE
|
UY33041A
(en)
*
|
2009-11-27 |
2011-06-30 |
Bayer Schering Pharma Aktienegesellschaft |
PROCEDURE FOR THE PREPARATION OF {4,6-DIAMINO-2- [1- (2-FLUOROBENCIL) -1H-PIRAZOLO [3,4-B] PIRIDIN-3-IL] PIRIMIDIN-5-IL} CARBAMATO DE METTILO AND ITS PURIFICATION FOR USE AS A PHARMACEUTICAL ACTIVE PRINCIPLE
|
CA2784010A1
(en)
*
|
2009-12-14 |
2011-06-23 |
Bayer Intellectual Property Gmbh |
Novel solvates of methyl{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate
|
WO2011095553A1
(en)
|
2010-02-05 |
2011-08-11 |
Bayer Schering Pharma Aktiengesellschaft |
Sgc stimulators or sgc activators in combination with pde5 inhbitors for the treatment of erectile dysfunction
|
JP6143461B2
(en)
*
|
2010-02-05 |
2017-06-07 |
アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
Treatment of cystic fibrosis in combination with sGC stimulator or sGC activator alone and PDE5 inhibitor
|
AU2011219746B2
(en)
|
2010-02-27 |
2015-04-23 |
Bayer Intellectual Property Gmbh |
Bisaryl-bonded aryltriazolones and use thereof
|
EP2549875B1
(en)
|
2010-03-25 |
2015-05-13 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
DE102010020553A1
(en)
|
2010-05-14 |
2011-11-17 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted 8-alkoxy-2-aminotetralin derivatives and their use
|
DE102010021637A1
(en)
|
2010-05-26 |
2011-12-01 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted 5-fluoro-1H-pyrazolopyridines and their use
|
NZ603799A
(en)
*
|
2010-05-26 |
2014-10-31 |
Bayer Ip Gmbh |
The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of systemic sclerosis (ssc).
|
WO2011149921A1
(en)
|
2010-05-27 |
2011-12-01 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
KR20130112848A
(en)
|
2010-06-02 |
2013-10-14 |
아레나 파마슈티칼스, 인크. |
Processes for the preparation of 5-ht2c receptor agonists
|
DE102010030187A1
(en)
|
2010-06-16 |
2011-12-22 |
Bayer Schering Pharma Aktiengesellschaft |
New 4-cyano-2-sulfonylphenyl-pyrazolyl-substituted pyridinones and pyrazinones compounds are human neutrophil elastase inhibitors, useful to treat and prevent e.g. pulmonary arterial hypertension and chronic obstructive pulmonary disease
|
EP2585055A1
(en)
*
|
2010-06-25 |
2013-05-01 |
Bayer Intellectual Property GmbH |
Use of stimulators and activators of soluble guanylate cyclase for treating sickle-cell anemia and conserving blood substitutes
|
DE102010030688A1
(en)
|
2010-06-30 |
2012-01-05 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted dicyanopyridines and their use
|
DE102011003315A1
(en)
|
2011-01-28 |
2012-08-02 |
Bayer Schering Pharma Aktiengesellschaft |
New 1H-pyrazolo(3,4-b)pyridine compounds are guanylate cyclase stimulators useful for treating and/or preventing e.g. heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, vascular disease, and fibrotic disorder
|
DE102010031148A1
(en)
|
2010-07-09 |
2012-01-12 |
Bayer Schering Pharma Ag |
New 1-(2-fluoro-benzyl)-1H-pyrazolo(3,4-b)pyridine compounds are guanylate cyclase stimulators useful to treat and/or prevent heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, and vascular disease
|
CN106977530A
(en)
|
2010-07-09 |
2017-07-25 |
拜耳知识产权有限责任公司 |
Ring fusion pyrimidine and triazine and its be used for treat and/or prevention of cardiovascular disease purposes
|
DE102010031149A1
(en)
|
2010-07-09 |
2012-01-12 |
Bayer Schering Pharma Aktiengesellschaft |
New 1H-pyrazolo(3,4-b)pyridine compounds are guanylate cyclase stimulators useful to treat and/or prevent heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, and vascular disease
|
DE102011007891A1
(en)
|
2011-04-21 |
2012-10-25 |
Bayer Pharma Aktiengesellschaft |
New ring-fused 4-aminopyrimidine compounds are guanylate cyclase stimulators useful to treat and/or prevent e.g. heart failure, angina pectoris, hypertonia, pulmonary hypertonia, ischemia, vascular disease and renal insufficiency
|
JP5940062B2
(en)
|
2010-07-09 |
2016-06-29 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH |
Ring-fused 4-aminopyrimidine and its use as a stimulant of soluble guanylate cyclase
|
MX2013000537A
(en)
|
2010-07-14 |
2013-01-29 |
Novartis Ag |
Ip receptor agonist heterocyclic compounds.
|
DE102010031667A1
(en)
|
2010-07-22 |
2012-01-26 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted methyl pyrimidin-5-ylcarbamates and their use
|
DE102010031665A1
(en)
|
2010-07-22 |
2012-01-26 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted oxazolidinones and oxazinones and their use
|
DE102010031666A1
(en)
|
2010-07-22 |
2012-01-26 |
Bayer Schering Pharma Aktiengesellschaft |
Carbamate-substituted diaminopyrimidines and their use
|
EP3485878A1
(en)
|
2010-09-01 |
2019-05-22 |
Arena Pharmaceuticals, Inc. |
Modified-release dosage forms of 5-ht2c agonists useful for weight management
|
EP2611449A1
(en)
|
2010-09-01 |
2013-07-10 |
Arena Pharmaceuticals, Inc. |
Administration of lorcaserin to individuals with renal impairment
|
CA2808904A1
(en)
|
2010-09-01 |
2012-03-08 |
Arena Pharmaceuticals, Inc. |
Non-hygroscopic salts of 5-ht2c agonists
|
SG188364A1
(en)
|
2010-09-01 |
2013-04-30 |
Arena Pharm Inc |
Salts of lorcaserin with optically active acids
|
US20120058983A1
(en)
|
2010-09-02 |
2012-03-08 |
Bayer Pharma Aktiengesellschaft |
Adenosine A1 agonists for the treatment of glaucoma and ocular hypertension
|
DE102010040187A1
(en)
|
2010-09-02 |
2012-03-08 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted N-phenethyl-triazolone acetamides and their use
|
DE102010040233A1
(en)
|
2010-09-03 |
2012-03-08 |
Bayer Schering Pharma Aktiengesellschaft |
Bicyclic aza heterocycles and their use
|
DE102010040924A1
(en)
|
2010-09-16 |
2012-03-22 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted phenylacet and phenylpropanamides and their use
|
EP2632551B1
(en)
|
2010-10-28 |
2016-07-06 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
DE102010043379A1
(en)
|
2010-11-04 |
2012-05-10 |
Bayer Schering Pharma Aktiengesellschaft |
Substituted 6-fluoro-1H-pyrazolo [4,3-b] pyridines and their use
|
DE102010043380A1
(en)
|
2010-11-04 |
2012-05-10 |
Bayer Schering Pharma Aktiengesellschaft |
Benzyl-substituted carbamates and their use
|
CN102485724B
(en)
*
|
2010-12-06 |
2015-08-12 |
中国人民解放军军事医学科学院毒物药物研究所 |
Substituted thiophene base pyrazolo-pyridines and medicinal use thereof
|
DE102011006974A1
(en)
|
2011-04-07 |
2012-10-11 |
Bayer Pharma Aktiengesellschaft |
New substituted 1-benzylcycloalkylcarboxylic acid compounds are soluble guanylate cyclase activators useful to treat and/or prevent e.g. heart failure, angina pectoris, hypertension, ischemia and vascular disease
|
DE102010062544A1
(en)
|
2010-12-07 |
2012-06-14 |
Bayer Schering Pharma Aktiengesellschaft |
New substituted 1-benzylcycloalkylcarboxylic acid compounds are soluble guanylate cyclase activators useful to treat and/or prevent e.g. heart failure, angina pectoris, hypertension, pulmonary hypertension and vascular disease
|
AU2011340721A1
(en)
|
2010-12-07 |
2013-06-20 |
Bayer Intellectual Property Gmbh |
Substituted 1-benzylcycloalkylcarboxlic acids and use thereof
|
DE102012200356A1
(en)
|
2012-01-11 |
2013-07-11 |
Bayer Intellectual Property Gmbh |
New substituted imidazopyrid(az)ine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency
|
DE102011075399A1
(en)
|
2011-05-06 |
2012-11-08 |
Bayer Pharma Aktiengesellschaft |
New substituted imidazopyrid(az)ine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency
|
DE102011007272A1
(en)
|
2011-04-13 |
2012-10-18 |
Bayer Pharma Aktiengesellschaft |
Branched 3-phenylpropionic acid derivatives and their use
|
DE102011007890A1
(en)
|
2011-04-21 |
2012-10-25 |
Bayer Pharma Aktiengesellschaft |
New fluoroalkyl-substituted pyrazolopyridine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency
|
DE102012200357A1
(en)
|
2012-01-11 |
2013-07-11 |
Bayer Intellectual Property Gmbh |
New fluoroalkyl-substituted pyrazolopyridine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency
|
CA2833698A1
(en)
|
2011-04-21 |
2012-10-26 |
Bayer Intellectual Property Gmbh |
Fluoroalkyl-substituted pyrazolopyridines and use thereof
|
ES2592267T3
(en)
|
2011-05-06 |
2016-11-29 |
Bayer Intellectual Property Gmbh |
Imidazopyridines and substituted imidazopyridazines and their use
|
DE102011075398A1
(en)
|
2011-05-06 |
2012-11-08 |
Bayer Pharma Aktiengesellschaft |
Substituted imidazopyridazines and their use
|
EA201391769A1
(en)
|
2011-05-30 |
2014-04-30 |
Астеллас Фарма Инк. |
IMIDAZOPIRIDINE CONNECTIONS
|
CA2840552A1
(en)
|
2011-07-01 |
2013-01-10 |
Bayer Intellectual Property Gmbh |
Relaxin fusion polypeptides and uses thereof
|
DE102012200354A1
(en)
|
2012-01-11 |
2013-07-11 |
Bayer Intellectual Property Gmbh |
New heteroaryl-substituted pyrazolopyridine compounds are soluble guanylate cyclase stimulators, useful to treat e.g. heart disease, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular disease or renal insufficiency
|
AU2012280246A1
(en)
|
2011-07-06 |
2014-01-23 |
Bayer Intellectual Property Gmbh |
Heteroaryl-substituted pyrazolopyridines and use thereof as soluble guanylate cyclase stimulators
|
DE102011078715A1
(en)
|
2011-07-06 |
2013-01-10 |
Bayer Pharma AG |
New substituted pyrazolo-pyridine derivatives useful for treating and/or prophylaxis of e.g. congestive heart failure, angina pectoris, hypertension, pulmonary hypertension, ischemia, vascular diseases, renal failure, and fibrotic diseases
|
US20140148390A1
(en)
|
2011-07-08 |
2014-05-29 |
Bayer Intellectual Property Gmbh |
Fusion proteins releasing relaxin and uses thereof
|
US8883819B2
(en)
|
2011-09-01 |
2014-11-11 |
Irm Llc |
Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
|
EP2751106B1
(en)
|
2011-09-02 |
2017-10-18 |
Bayer Intellectual Property GmbH |
Substituted annellated pyrimidine and the use thereof
|
DE102012200351A1
(en)
|
2012-01-11 |
2013-07-11 |
Bayer Pharma Aktiengesellschaft |
New substituted annellated pyrimidine compounds are guanylate cyclase stimulators useful to treat and/or prevent heart failure, hypertension, ischemia, vascular disease, renal failure, thromboembolic disorders and fibrotic diseases
|
DE102011082041A1
(en)
|
2011-09-02 |
2013-03-07 |
Bayer Pharma AG |
New substituted fused pyrimidine compounds are guanylate cyclase stimulators useful to treat and/or prevent e.g. heart failure, hypertension, ischemia, vascular disease, renal failure, thromboembolic disorders and fibrotic diseases
|
PL2896617T3
(en)
|
2011-11-25 |
2017-07-31 |
Adverio Pharma Gmbh |
Method for producing substituted (z)-alpha-fluoro-beta-amino-acrylaldehydes
|
CN102491974B
(en)
|
2011-12-12 |
2013-08-07 |
南京药石药物研发有限公司 |
Method for synthesizing 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-formamidine hydrochloride
|
DE102012200360A1
(en)
|
2012-01-11 |
2013-07-11 |
Bayer Intellectual Property Gmbh |
Substituted triazines and their use
|
DE102012200349A1
(en)
*
|
2012-01-11 |
2013-07-11 |
Bayer Intellectual Property Gmbh |
Substituted fused pyrimidines and triazines and their use
|
DE102012200352A1
(en)
|
2012-01-11 |
2013-07-11 |
Bayer Intellectual Property Gmbh |
Substituted, fused imidazoles and pyrazoles and their use
|
EP2802589B1
(en)
|
2012-01-13 |
2016-01-06 |
Novartis AG |
Fused pyrroles as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
|
EP2802584B1
(en)
|
2012-01-13 |
2015-11-18 |
Novartis AG |
Salts of an ip receptor agonist
|
US20150005311A1
(en)
|
2012-01-13 |
2015-01-01 |
Novartis Ag |
IP receptor agonist heterocyclic compounds
|
EP2802585A1
(en)
|
2012-01-13 |
2014-11-19 |
Novartis AG |
Fused piperidines as ip receptor agonists for the treatment of pah and related disorders
|
EP2802582A1
(en)
|
2012-01-13 |
2014-11-19 |
Novartis AG |
Fused dihydropyrido [2,3 -b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
|
EP2802581A1
(en)
|
2012-01-13 |
2014-11-19 |
Novartis AG |
7,8- dihydropyrido [3, 4 - b]pyrazines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders
|
JP6140738B2
(en)
|
2012-03-06 |
2017-05-31 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH |
Substituted azabicycles and uses thereof
|
WO2013144191A1
(en)
|
2012-03-29 |
2013-10-03 |
Bayer Intellectual Property Gmbh |
Substituted 2-amino-3-cyanopyridines as inhibitors of sodium-calcium exchange and use thereof for cardiovascular diseases
|
KR20140144696A
(en)
|
2012-04-16 |
2014-12-19 |
도아 에이요 가부시키가이샤 |
Bicyclic compound
|
UA112897C2
(en)
|
2012-05-09 |
2016-11-10 |
Байєр Фарма Акцієнгезелльшафт |
BICYCLIC SUBSTITUTED URATILES AND THEIR APPLICATIONS FOR THE TREATMENT AND / OR PREVENTION OF DISEASES
|
DE102012208530A1
(en)
|
2012-05-22 |
2013-11-28 |
Bayer Pharma AG |
Substituted piperidinoacetamides and their use
|
US9387203B2
(en)
|
2012-07-20 |
2016-07-12 |
Bayer Pharma Aktiengesellschaft |
Substituted aminoindane- and aminotetralinecarboxylic acids and the use thereof
|
AU2013292046C1
(en)
|
2012-07-20 |
2018-03-15 |
Bayer Pharma Aktiengesellschaft |
Novel 5-aminotetrahydroquinoline-2-carboxylic acids and use thereof
|
RU2674670C1
(en)
|
2012-10-09 |
2018-12-12 |
Арена Фармасьютикалз, Инк. |
Method of correction of body mass
|
AU2013353117A1
(en)
|
2012-11-30 |
2015-06-04 |
Astellas Pharma Inc. |
Imidazopyridine compound
|
CN105189500A
(en)
|
2013-02-13 |
2015-12-23 |
诺华股份有限公司 |
IP receptor agonist heterocyclic compounds
|
SG11201506211RA
(en)
|
2013-02-21 |
2015-09-29 |
Adverio Pharma Gmbh |
Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
|
US9073921B2
(en)
|
2013-03-01 |
2015-07-07 |
Novartis Ag |
Salt forms of bicyclic heterocyclic derivatives
|
EP2961754B1
(en)
*
|
2013-03-01 |
2016-11-16 |
Bayer Pharma Aktiengesellschaft |
Benzyl-substituted pyrazolopyridines and use thereof
|
SG11201505974VA
(en)
*
|
2013-03-01 |
2015-09-29 |
Bayer Pharma AG |
Trifluormethyl-substituted ring-fused pyrimidines and use thereof
|
RS63108B1
(en)
|
2013-03-15 |
2022-04-29 |
Cyclerion Therapeutics Inc |
Sgc stimulators
|
US20160108039A1
(en)
*
|
2013-06-03 |
2016-04-21 |
Bayer Pharma Aktiengesellschaft |
Triazolopyridines as thrombin inhibitors for the treatment of thromboembolic diseases
|
ES2625744T3
(en)
|
2013-06-04 |
2017-07-20 |
Bayer Pharma Aktiengesellschaft |
Imidazo [1,2-a] pyridines substituted with 3-aryl and their use
|
WO2015004105A1
(en)
|
2013-07-10 |
2015-01-15 |
Bayer Pharma Aktiengesellschaft |
Benzyl-1h-pyrazolo[3,4-b]pyridines and use thereof
|
EP3024455A1
(en)
|
2013-07-25 |
2016-06-01 |
Bayer Pharma Aktiengesellschaft |
Sgc stimulators or sgc activators and pde5 inhibitors in combination with additional treatment for the therapy of cystic fibrosis
|
CN105992765A
(en)
*
|
2013-08-08 |
2016-10-05 |
拜耳制药股份公司 |
Substituted pyrazolo[1,5-a]-pyridine-3-carboxamides and use thereof
|
US20160221965A1
(en)
|
2013-09-16 |
2016-08-04 |
Bayer Pharma Aktiengesellschaft |
Disubstituted trifluoromethyl pyrimidinones and their use
|
MX2016004250A
(en)
|
2013-10-07 |
2016-07-12 |
Bayer Pharma AG |
Cyclic thienouracil-carboxamides and use thereof.
|
ES2718379T3
(en)
|
2013-10-15 |
2019-07-01 |
Toa Eiyo Ltd |
4-Aminomethylbenzoic acid derivative
|
CN104327107A
(en)
|
2013-10-17 |
2015-02-04 |
广东东阳光药业有限公司 |
Preparation method of fluoroquinolone antibiosis medicine
|
US20160256460A1
(en)
*
|
2013-11-01 |
2016-09-08 |
Bergen Teknologioverføring As |
Activators or stimulators of soluble guanylate cyclase for use in treating chronic fatigue syndrome
|
EP3066098A1
(en)
|
2013-11-08 |
2016-09-14 |
Bayer Pharma Aktiengesellschaft |
Substituted uracils and use thereof
|
CN105873919A
(en)
|
2013-11-08 |
2016-08-17 |
拜耳医药股份有限公司 |
Substituted uracils as chymase inhibitors
|
WO2015088885A1
(en)
|
2013-12-11 |
2015-06-18 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
US9783552B2
(en)
|
2013-12-11 |
2017-10-10 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase activators
|
CN106304835A
(en)
*
|
2013-12-11 |
2017-01-04 |
铁木医药有限公司 |
Sgc stimulant
|
JOP20200052A1
(en)
|
2013-12-19 |
2017-06-16 |
Bayer Pharma AG |
Substituted piperidinyl-tetrahydroquinolines and their use as alpha-2c adrenoreceptor antagonists
|
WO2015091417A1
(en)
|
2013-12-19 |
2015-06-25 |
Bayer Pharma Aktiengesellschaft |
Substituted piperidinyl-tetrahydroquinolines
|
CA2934132A1
(en)
|
2013-12-19 |
2015-06-25 |
Bayer Pharma Aktiengesellschaft |
Substituted bipiperidinyl derivatives as adrenoreceptor alpha 2c antagonists
|
US9624199B2
(en)
|
2013-12-19 |
2017-04-18 |
Bayer Pharma Aktiengesellschaft |
Substituted bipiperidinyl derivatives
|
WO2015095515A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Sgc activators for the treatment of glaucoma
|
US20160324856A1
(en)
|
2014-01-13 |
2016-11-10 |
Ironwood Pharmaceuticals, Inc. |
Use of sgc stimulators for the treatment of neuromuscular disorders
|
US9688699B2
(en)
|
2014-02-19 |
2017-06-27 |
Bayer Pharma Aktiengesellschaft |
3-(pyrimidine-2-yl)imidazo[1,2-a]pyridines
|
CA2944614A1
(en)
|
2014-04-03 |
2015-10-08 |
Bayer Pharma Aktiengesellschaft |
2,5-disubstituted cyclopentane carboxylic acids for the treatment of respiratoy tract diseases
|
EP3126339A1
(en)
|
2014-04-03 |
2017-02-08 |
Bayer Pharma Aktiengesellschaft |
2,5-disubstituted cyclopentane carboxylic acids and use thereof
|
CN106458938A
(en)
|
2014-04-03 |
2017-02-22 |
拜耳制药股份公司 |
Chiral 2,5-disubstituted cyclopentanecarboxylic acid derivatives and use thereof
|
BR112016024533A8
(en)
|
2014-04-24 |
2021-03-30 |
Novartis Ag |
amino pyrazine derivatives as phosphatidylinositol 3-kinase or salt inhibitors, their use, and pharmaceutical composition and combination
|
PT3134396T
(en)
|
2014-04-24 |
2019-12-16 |
Novartis Ag |
Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
|
AU2014391610B2
(en)
|
2014-04-24 |
2018-01-25 |
Novartis Ag |
Pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
|
WO2015187470A1
(en)
|
2014-06-04 |
2015-12-10 |
Merck Sharp & Dohme Corp. |
Imidazo-pyrazine derivatives useful as soluble guanylate cyclase activators
|
CN116655630A
(en)
|
2014-08-01 |
2023-08-29 |
拜耳医药股份有限公司 |
Method for preparing compound and purification thereof for use as active pharmaceutical ingredient
|
CN107108658A
(en)
|
2014-08-29 |
2017-08-29 |
拜耳医药股份有限公司 |
Substituted cyclic pyrimidin and application thereof
|
CA2959199A1
(en)
|
2014-08-29 |
2016-03-03 |
Bayer Pharma Aktiengesellschaft |
Amino-substituted annulated pyrimidines and use thereof
|
US10189788B2
(en)
|
2014-09-09 |
2019-01-29 |
Bayer Pharma Aktiengesellschaft |
Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
|
US10844064B2
(en)
|
2014-09-17 |
2020-11-24 |
Cyclerion Therapeutics, Inc. |
sGC stimulators
|
JP6624616B2
(en)
|
2014-09-17 |
2019-12-25 |
サイクレリオン・セラピューティクス,インコーポレーテッド |
sGC stimulant
|
WO2016044445A2
(en)
|
2014-09-17 |
2016-03-24 |
Ironwood Pharmaceuticals, Inc. |
sGC STIMULATORS
|
US10138236B2
(en)
|
2014-09-24 |
2018-11-27 |
Bayer Pharma Aktiengesellschaft |
Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives
|
CN107074783B
(en)
|
2014-11-03 |
2020-06-05 |
拜耳制药股份公司 |
Hydroxyalkyl substituted phenyl triazole derivatives and uses thereof
|
CN104374861B
(en)
*
|
2014-11-10 |
2016-03-02 |
广东东阳光药业有限公司 |
The method of the related substance of the western croak bulk drug of a kind of HPLC separation determination Leo
|
CN104434845B
(en)
*
|
2014-11-12 |
2017-12-05 |
广东东阳光药业有限公司 |
A kind of solid pharmaceutical preparation for including the western croak of Leo
|
TW201625635A
(en)
|
2014-11-21 |
2016-07-16 |
默沙東藥廠 |
Triazolo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
|
CA2969268A1
(en)
|
2014-12-02 |
2016-06-09 |
Bayer Pharma Aktiengesellschaft |
Heteroaryl-substituted imidazo[1,2-a]pyridines and their use
|
CN105777743A
(en)
*
|
2014-12-19 |
2016-07-20 |
奥浦顿(上海)医药科技有限公司 |
Preparation method and application of pyrazolo[3, 4-b]pyridine compound intermediate
|
CN104530044B
(en)
*
|
2014-12-31 |
2016-07-13 |
安徽联创生物医药股份有限公司 |
A kind of synthetic method of the western croak of Leo
|
WO2016113205A1
(en)
|
2015-01-13 |
2016-07-21 |
Bayer Pharma Aktiengesellschaft |
Substituted pentafluoroethyl pyrimidinones and use thereof
|
WO2016113415A1
(en)
|
2015-01-16 |
2016-07-21 |
Sandoz Ag |
Process for the preparation of riociguat essentially free from genotoxic impurities
|
UY36586A
(en)
|
2015-03-26 |
2016-10-31 |
Bayer Pharma AG |
HETEROCICLILMETILTIENOURACILOS AND USE OF THE SAME
|
EP3291811B1
(en)
|
2015-05-06 |
2019-08-07 |
Bayer Pharma Aktiengesellschaft |
The use of sgc stimulators, sgc activators, alone and combinations with pde5 inhibitors for the treatment of digital ulcers (du) concomitant to systemic sclerosis (ssc)
|
US10245264B2
(en)
|
2015-05-27 |
2019-04-02 |
Merck Sharp & Dohme Corp. |
Substituted imidazo[1,2-a]pyrazines as soluble guanylate cyclase activators
|
US10213429B2
(en)
|
2015-05-28 |
2019-02-26 |
Merck Sharp & Dohme Corp. |
Imidazo-pyrazinyl derivatives useful as soluble guanylate cyclase activators
|
SI3325013T2
(en)
|
2015-07-23 |
2023-11-30 |
Bayer Pharma Aktiengesellschaft |
Stimulators / activators of soluble guanylat cyclase in combination with a nep-inhibitor and/or an angiotensin aii-antagonist and the use thereof
|
WO2017025981A1
(en)
*
|
2015-08-13 |
2017-02-16 |
Msn Laboratories Private Limited |
Process for the preparation of methyl 4,6-diamino-2-[l-(2-fhiorobenzvr)-lh-pyrazolo i3,4-blpvridin-3-vn-5-pyrimidinyl(methvl)carbamate and its polymorphs thereof
|
LT3337800T
(en)
|
2015-08-21 |
2019-08-12 |
Bayer Pharma Aktiengesellschaft |
Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carboxamide and the purification thereof for use as an active pharmaceutical ingredient
|
KR20180074793A
(en)
|
2015-11-13 |
2018-07-03 |
바이엘 파마 악티엔게젤샤프트 |
4- (4-cyano-2-thioaryl) dihydropyrimidinone for chronic wound treatment
|
GEP20207104B
(en)
|
2015-12-10 |
2020-05-11 |
Bayer Pharma AG |
2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
|
US10414765B2
(en)
|
2015-12-10 |
2019-09-17 |
Bayer Pharma Aktiengesellschaft |
Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same
|
EP3389655A2
(en)
|
2015-12-14 |
2018-10-24 |
Ironwood Pharmaceuticals, Inc. |
USE OF sGC STIMULATORS FOR THE TREATMENT OF GASTROINTESTINAL SPHINCTER DYSFUNCTION
|
WO2017103760A1
(en)
*
|
2015-12-15 |
2017-06-22 |
Alembic Pharmaceuticals Limited |
Novel polymorph of riociguat and its process for the preparation
|
CN105461715B
(en)
*
|
2015-12-15 |
2017-03-29 |
郑州大明药物科技有限公司 |
A kind of synthetic method of the western croak intermediate of Leo
|
WO2017107052A1
(en)
|
2015-12-22 |
2017-06-29 |
Merck Sharp & Dohme Corp. |
Soluble guanylate cyclase stimulators
|
WO2017121692A1
(en)
|
2016-01-15 |
2017-07-20 |
Bayer Pharma Aktiengesellschaft |
Substituted sulfamides and use of same
|
WO2017121700A1
(en)
|
2016-01-15 |
2017-07-20 |
Bayer Pharma Aktiengesellschaft |
1,3-disubstituted 1h-pyrazolo[3,4-b]pyridine derivatives and use thereof as stimulators of soluble guanylate cyclase
|
WO2017121693A1
(en)
|
2016-01-15 |
2017-07-20 |
Bayer Pharma Aktiengesellschaft |
Substituted thiazole and thiadiazole amides, and use thereof
|
WO2017153234A1
(en)
|
2016-03-09 |
2017-09-14 |
Bayer Pharma Aktiengesellschaft |
Substituted n-cyclo-2-aryl-quinoline-4-carboxamides and use thereof
|
WO2017153231A1
(en)
|
2016-03-09 |
2017-09-14 |
Bayer Pharma Aktiengesellschaft |
Substituted n-cyclo-2-aryl-isoquinolinone-4-carboxamides and use thereof
|
WO2017153235A1
(en)
|
2016-03-09 |
2017-09-14 |
Bayer Pharma Aktiengesellschaft |
Substituted n-cyclo-3-aryl-1-naphthamides and use thereof
|
US9988367B2
(en)
|
2016-05-03 |
2018-06-05 |
Bayer Pharma Aktiengesellschaft |
Amide-substituted pyridinyltriazole derivatives and uses thereof
|
WO2017191117A1
(en)
|
2016-05-03 |
2017-11-09 |
Bayer Pharma Aktiengesellschaft |
V1a receptor antagonists for use in the treatment of renal diseases
|
WO2017191105A1
(en)
|
2016-05-03 |
2017-11-09 |
Bayer Pharma Aktiengesellschaft |
Amide-substituted aryltriazole derivatives and uses thereof
|
AR108265A1
(en)
|
2016-05-03 |
2018-08-01 |
Bayer Pharma AG |
FENILTRIAZOL DERIVATIVES REPLACED WITH AMIDA AND USES OF THESE
|
US10525041B2
(en)
|
2016-05-03 |
2020-01-07 |
Bayer Pharma Aktiengesellschaft |
Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
|
EP3452457B1
(en)
|
2016-05-03 |
2020-03-18 |
Bayer Pharma Aktiengesellschaft |
Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
|
WO2017191114A1
(en)
|
2016-05-03 |
2017-11-09 |
Bayer Aktiengesellschaft |
Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
|
JOP20170113B1
(en)
|
2016-05-09 |
2023-03-28 |
Bayer Pharma AG |
Substituted 5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridin-3(2H)-ones and 2,5,6,7-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]triazol-3-ones and use thereof
|
WO2017197555A1
(en)
|
2016-05-16 |
2017-11-23 |
Merck Sharp & Dohme Corp. |
Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators
|
EP3458063A4
(en)
|
2016-05-18 |
2020-02-26 |
Merck Sharp & Dohme Corp. |
Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders
|
CA3029374A1
(en)
|
2016-07-07 |
2018-01-11 |
Ironwood Pharmaceuticals, Inc. |
Phosphorus prodrugs of sgc stimulators
|
JP2019524710A
(en)
|
2016-07-07 |
2019-09-05 |
アイアンウッド ファーマシューティカルズ インコーポレイテッド |
Solid form of SGC stimulant
|
CN109689654A
(en)
|
2016-07-11 |
2019-04-26 |
拜耳医药股份有限公司 |
1- pyridyl group-naphthyridines -3- benzamide type and application thereof that 7- replaces
|
JOP20190005A1
(en)
*
|
2016-07-20 |
2019-01-20 |
Bayer Ag |
Substituted diazahetero-bicyclic compounds and their use
|
WO2018041771A1
(en)
|
2016-09-02 |
2018-03-08 |
Bayer Pharma Aktiengesellschaft |
(1-methylcyclopropyl)methyl-substituted thienouraciles and use thereof
|
SG11201901729YA
(en)
|
2016-09-02 |
2019-03-28 |
Ironwood Pharmaceuticals Inc |
Fused bicyclic sgc stimulators
|
JOP20190045A1
(en)
|
2016-09-14 |
2019-03-14 |
Bayer Ag |
7-substituted 1-aryl-naphthyridine-3-carboxylic acid amides and use thereof
|
EP3296298A1
(en)
|
2016-09-14 |
2018-03-21 |
Bayer Pharma Aktiengesellschaft |
7-substituted 1-aryl-naphthyridin-3-carboxamides and their use
|
US20200016159A1
(en)
|
2016-09-23 |
2020-01-16 |
Bayer Aktiengesellschaft |
N3-cyclically substituted thienouracils and use thereof
|
CN109890379A
(en)
|
2016-10-11 |
2019-06-14 |
拜耳制药股份公司 |
Combination product comprising sGC activator and mineralocorticoid receptor antagonists
|
EP3525779A1
(en)
|
2016-10-11 |
2019-08-21 |
Bayer Pharma Aktiengesellschaft |
Combination containing sgc stimulators and mineralocorticoid receptor antagonists
|
JOP20190080A1
(en)
|
2016-10-14 |
2019-04-11 |
Bayer Pharma AG |
Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof
|
CN107964011A
(en)
*
|
2016-10-19 |
2018-04-27 |
中国人民解放军军事医学科学院毒物药物研究所 |
Substituted pyrazolopyridines analog derivative and its medical usage
|
WO2018073144A1
(en)
|
2016-10-20 |
2018-04-26 |
Bayer Pharma Aktiengesellschaft |
Hydroxyalkyl-substituted triazole derivatives and uses thereof
|
MX2019005342A
(en)
|
2016-11-08 |
2019-10-02 |
Cyclerion Therapeutics Inc |
Treatment of cns diseases with sgc stimulators.
|
CA3042713A1
(en)
*
|
2016-11-08 |
2018-05-17 |
Cyclerion Therapeutics, Inc. |
Sgc stimulators
|
WO2018111795A2
(en)
|
2016-12-13 |
2018-06-21 |
Ironwood Pharmaceuticals, Inc. |
Use of sgc stimulators for the treatment of esophageal motility disorders
|
EA202192558A1
(en)
*
|
2016-12-14 |
2021-12-07 |
Байер Акциенгезельшафт |
SUBSTITUTED DIAZHETEROBICYCLIC COMPOUNDS AND THEIR APPLICATIONS
|
AU2017378409A1
(en)
|
2016-12-14 |
2019-07-04 |
Respira Therapeutics, Inc. |
Methods and compositions for treatment of pulmonary hypertension and other lung disorders
|
JOP20190148A1
(en)
|
2016-12-21 |
2019-06-18 |
Bayer Pharma AG |
Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
|
EP3338803A1
(en)
|
2016-12-21 |
2018-06-27 |
Bayer Pharma Aktiengesellschaft |
Pharmaceutical dosage forms containing inhibitors for task-1 and task-3 channels and their use in therapy of respiratory disorders
|
EP3338764A1
(en)
|
2016-12-21 |
2018-06-27 |
Bayer Pharma Aktiengesellschaft |
Pharmaceutical dosage forms containing inhibitors for task-1 and task-3 channels and their use in therapy of respiratory disorders
|
JOP20190141A1
(en)
|
2016-12-21 |
2019-06-12 |
Bayer Pharma AG |
Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
|
WO2018130226A1
(en)
*
|
2017-01-16 |
2018-07-19 |
苏州科睿思制药有限公司 |
New crystal form of riociguat, preparation method and use thereof
|
CA3052639A1
(en)
|
2017-02-08 |
2018-08-16 |
Bristol-Myers Squibb Company |
Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
|
WO2018153899A1
(en)
|
2017-02-22 |
2018-08-30 |
Bayer Pharma Aktiengesellschaft |
Selective partial adenosine a1 receptor agonists in combination with soluble guanylyl cyclase (sgc) stimulators and/or activators
|
JP7107963B2
(en)
|
2017-04-10 |
2022-07-27 |
バイエル・アクチエンゲゼルシヤフト |
Substituted N-arylethyl-2-arylquinoline-4-carboxamides and uses thereof
|
TWI770157B
(en)
|
2017-04-10 |
2022-07-11 |
德商拜耳廠股份有限公司 |
Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof
|
US11242335B2
(en)
|
2017-04-11 |
2022-02-08 |
Sunshine Lake Pharma Co., Ltd. |
Fluorine-substituted indazole compounds and uses thereof
|
CN108690016B
(en)
*
|
2017-04-11 |
2022-08-12 |
广东东阳光药业有限公司 |
Pyrazolopyridines and uses thereof
|
JOP20190284A1
(en)
|
2017-06-14 |
2019-12-11 |
Bayer Pharma AG |
Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
|
WO2018227427A1
(en)
|
2017-06-14 |
2018-12-20 |
Bayer Aktiengesellschaft |
Substituted bridged diazepane derivatives and use thereof
|
WO2019081299A1
(en)
|
2017-10-24 |
2019-05-02 |
Bayer Pharma Aktiengesellschaft |
Amine substituted triazole derivatives and uses thereof
|
US11230540B2
(en)
|
2017-10-24 |
2022-01-25 |
Bayer Pharma Aktiengesellschaft |
Substituted triazole derivatives and uses thereof
|
EP3700898A1
(en)
|
2017-10-24 |
2020-09-02 |
Bayer Pharma Aktiengesellschaft |
Substituted triazole derivatives and uses thereof
|
WO2019081291A1
(en)
|
2017-10-24 |
2019-05-02 |
Bayer Aktiengesellschaft |
Prodrugs of substituted triazole derivatives and uses thereof
|
EP3700897A1
(en)
|
2017-10-24 |
2020-09-02 |
Bayer Pharma Aktiengesellschaft |
Substituted triazole derivatives and uses thereof
|
WO2019081456A1
(en)
|
2017-10-24 |
2019-05-02 |
Bayer Aktiengesellschaft |
Use of activators and stimulators of sgc comprising a beta2 subunit
|
CR20200173A
(en)
|
2017-10-24 |
2020-06-26 |
Bayer Pharma AG |
Substituted imidazopyridine amides and use thereof
|
PL3700913T3
(en)
|
2017-10-24 |
2022-02-21 |
Bayer Aktiengesellschaft |
Prodrugs of substituted triazole derivatives and uses thereof
|
US11173151B2
(en)
|
2017-10-24 |
2021-11-16 |
Bayer Aktiengesellschaft |
Substituted triazole derivatives and uses thereof
|
CA3081775A1
(en)
|
2017-11-07 |
2019-05-16 |
Bayer Aktiengesellschaft |
Substituted 2,4-dihydro-3h-1,2,4-triazol-3-ones and use of same
|
MX2020005646A
(en)
|
2017-12-01 |
2020-08-20 |
Bayer Pharma AG |
METHOD FOR PRODUCING (3<i>S</i>)-3-(4-CHLOR-3-{[(2<i>S,</i>3<i>R< /i>)-2-(4-CHLORPHENYL)-4,4,4-TRIFLUOR-3-METHYLBUTANOYL]AMINO}PHE NYL)-3-CYCLO-PROPYLPROPANOIC ACID AND THE CRYSTALLINE FORM THEREOF FOR USE AS A PHARMACEUTICAL INGREDIENT.
|
JP7337067B2
(en)
*
|
2017-12-19 |
2023-09-01 |
サイクレリオン・セラピューティクス,インコーポレーテッド |
sGC stimulant
|
MX2020009183A
(en)
|
2018-03-07 |
2020-10-08 |
Cyclerion Therapeutics Inc |
Crystalline forms of an sgc stimulator.
|
EP3553079A1
(en)
|
2018-04-12 |
2019-10-16 |
Bayer Aktiengesellschaft |
C-type natriuretic peptide engrafted antibodies
|
EP3553081A1
(en)
|
2018-04-12 |
2019-10-16 |
Bayer Aktiengesellschaft |
Atrial natriuretic peptide engrafted antibodies
|
EP3553082A1
(en)
|
2018-04-12 |
2019-10-16 |
Bayer Aktiengesellschaft |
Brain natriuretic peptide engrafted antibodies
|
CN112055584A
(en)
|
2018-04-30 |
2020-12-08 |
拜耳公司 |
Use of sGC activators and sGC stimulators for the treatment of cognitive disorders
|
SG11202011018PA
(en)
|
2018-05-15 |
2020-12-30 |
Bayer Ag |
1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
|
US20220324865A1
(en)
|
2018-05-17 |
2022-10-13 |
Bayer Aktiengesellschaft |
Substituted dihydropyrazolo pyrazine carboxamide derivatives
|
WO2019223629A1
(en)
|
2018-05-22 |
2019-11-28 |
广东东阳光药业有限公司 |
Phenyl-substituted dihydronaphthyridine compound and use thereof
|
EP3574905A1
(en)
|
2018-05-30 |
2019-12-04 |
Adverio Pharma GmbH |
Method of identifying a subgroup of patients suffering from dcssc which benefits from a treatment with sgc stimulators and sgc activators in a higher degree than a control group
|
MX2021000363A
(en)
|
2018-07-11 |
2021-04-29 |
Cyclerion Therapeutics Inc |
USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONRIAL DISORDERS.
|
CA3107169A1
(en)
|
2018-07-24 |
2020-01-30 |
Bayer Aktiengesellschaft |
Pharmaceutical dosage form which can be administered orally and has modified release
|
EP3826619A1
(en)
|
2018-07-24 |
2021-06-02 |
Bayer Aktiengesellschaft |
Pharmaceutical dosage form which can be administered orally and has modified release
|
US10905667B2
(en)
|
2018-07-24 |
2021-02-02 |
Bayer Pharma Aktiengesellschaft |
Orally administrable modified-release pharmaceutical dosage form
|
MA54275A
(en)
|
2018-11-27 |
2022-03-02 |
Bayer Ag |
METHOD FOR THE MANUFACTURE OF PHARMACEUTICAL FORMS CONTAINING INHIBITORS OF THE TASK-1 AND TASK-3 CHANNEL AND THEIR USE FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
BR112021009958A2
(en)
|
2018-11-28 |
2021-08-17 |
Topadur Pharma Ag |
dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and their uses
|
WO2020164008A1
(en)
|
2019-02-13 |
2020-08-20 |
Bayer Aktiengesellschaft |
Process for the preparation of porous microparticles
|
WO2020165031A1
(en)
|
2019-02-15 |
2020-08-20 |
Bayer Aktiengesellschaft |
Substituted isoquinoline-piperidinylmethanone derivatives
|
WO2020216669A1
(en)
|
2019-04-23 |
2020-10-29 |
Bayer Aktiengesellschaft |
Phenyl-substituted imidazopyridine amides and use thereof
|
CN114585637A
(en)
|
2019-05-07 |
2022-06-03 |
拜耳公司 |
MASP inhibiting compounds and uses thereof
|
WO2020245342A1
(en)
|
2019-06-07 |
2020-12-10 |
Bayer Aktiengesellschaft |
The use of sgc activators for the treatment of ophthalmologic diseases
|
JP2023500263A
(en)
|
2019-11-06 |
2023-01-05 |
バイエル・アクチエンゲゼルシヤフト |
Inhibitors of the adrenergic receptor ADRAC2
|
WO2021094209A1
(en)
|
2019-11-12 |
2021-05-20 |
Bayer Aktiengesellschaft |
Substituted pyrrolo triazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
|
WO2021094208A1
(en)
|
2019-11-12 |
2021-05-20 |
Bayer Aktiengesellschaft |
Substituted imidazo pyrimidine ep3 antagonists
|
WO2021094210A1
(en)
|
2019-11-12 |
2021-05-20 |
Bayer Aktiengesellschaft |
Substituted pyrazine carboxamide derivatives as prostaglandin ep3 receptor antagonists
|
EP3822265A1
(en)
|
2019-11-15 |
2021-05-19 |
Bayer AG |
Substituted hydantoinamides as adamts7 antagonists
|
EP3822268A1
(en)
|
2019-11-15 |
2021-05-19 |
Bayer Aktiengesellschaft |
Substituted hydantoinamides as adamts7 antagonists
|
JP2023507626A
(en)
|
2019-12-16 |
2023-02-24 |
テナックス・セラピューティクス,インコーポレイテッド |
Levosimendan for the treatment of pulmonary hypertension with preserved ejection fraction heart failure (PH-HF-pEF)
|
CA3170507A1
(en)
|
2020-02-21 |
2021-08-26 |
Universiteit Maastricht |
Use of a soluble guanylate cyclase (sgc) stimulator or of a combination of a sgc stimulator and an sgc activator for conditions wherein the heme group of sgc is oxidized or wherein sgc is deficient in heme
|
US20230083417A1
(en)
|
2020-02-26 |
2023-03-16 |
Universiteit Maastricht |
Therapeutic combination for the treatment of brain ischemia and said therapeutic combination for use in the treatment of brain ischemia
|
WO2021195403A1
(en)
|
2020-03-26 |
2021-09-30 |
Cyclerion Therapeutics, Inc. |
Deuterated sgc stimulators
|
WO2021202546A1
(en)
|
2020-03-31 |
2021-10-07 |
Cyclerion Therapeutics, Inc. |
Early drug interventions to reduce covid-19 related respiratory distress, need for ventilator assistance and death
|
WO2022057836A1
(en)
*
|
2020-09-16 |
2022-03-24 |
南京明德新药研发有限公司 |
Benzourea ring derivative, and preparation method therefor and use thereof
|
EP4011904A1
(en)
|
2020-12-14 |
2022-06-15 |
Bayer Aktiengesellschaft |
Masp inhibitory compounds and uses thereof
|
EP4240750A1
(en)
|
2020-11-04 |
2023-09-13 |
Bayer Aktiengesellschaft |
Masp inhibitory compounds and uses thereof
|
WO2022112213A1
(en)
|
2020-11-30 |
2022-06-02 |
Bayer Aktiengesellschaft |
Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide
|
EP4011874A1
(en)
|
2020-12-10 |
2022-06-15 |
Bayer Aktiengesellschaft |
Substituted pyrazolo piperidine carboxylic acids
|
WO2022122916A1
(en)
|
2020-12-10 |
2022-06-16 |
Bayer Aktiengesellschaft |
Substituted pyrazolyl piperidine carboxylic acids
|
AU2021398486A1
(en)
|
2020-12-10 |
2023-06-22 |
Bayer Aktiengesellschaft |
The use of sgc activators for the treatment of ophthalmologic diseases
|
JP2023552583A
(en)
|
2020-12-10 |
2023-12-18 |
バイエル・アクチエンゲゼルシヤフト |
Substituted pyrazolopiperidine carboxylic acids
|
EP4011873A1
(en)
|
2020-12-10 |
2022-06-15 |
Bayer Aktiengesellschaft |
Substituted pyrazolo piperidine carboxylic acids
|
WO2022225903A1
(en)
|
2021-04-20 |
2022-10-27 |
Cyclerion Therapeutics, Inc. |
Sgc stimulators
|
TW202308634A
(en)
|
2021-04-20 |
2023-03-01 |
美商賽克瑞恩醫療公司 |
Treatment of cns diseases with sgc stimulators
|
WO2022228365A1
(en)
*
|
2021-04-27 |
2022-11-03 |
南京明德新药研发有限公司 |
Derivative of six-membered heteroaromatic urea ring and application thereof
|
WO2022265984A1
(en)
|
2021-06-14 |
2022-12-22 |
Curtails Llc |
Use of nep inhibitors for the treatment of gastrointestinal sphincter disorders
|
WO2023018795A1
(en)
|
2021-08-11 |
2023-02-16 |
Curtails Llc |
Nep inhibitors for the treatment of laminitis
|
WO2023126437A1
(en)
|
2021-12-29 |
2023-07-06 |
Bayer Aktiengesellschaft |
Treatment of cardiopulmonary disorders
|
TW202342035A
(en)
|
2021-12-29 |
2023-11-01 |
德商拜耳廠股份有限公司 |
Pharmaceutical dry powder inhalation formulation
|
AR128147A1
(en)
|
2021-12-29 |
2024-03-27 |
Bayer Ag |
PROCEDURE FOR THE PREPARATION OF ACID (5S)-[2-(4-CARBOXYPHENYL)ETHYL][2-(2-[3-CHLORO-4-(TRIFLUOROMETHYL)BIPHENYL-4-IL]METHOXYPHENYL)ETHYL]AMINO-5 ,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLIC AND ITS CRYSTALLINE FORMS FOR USE AS A PHARMACEUTICALLY ACTIVE COMPOUND
|
WO2023237577A1
(en)
|
2022-06-09 |
2023-12-14 |
Bayer Aktiengesellschaft |
Soluble guanylate cyclase activators for use in the treatment of heart failure with preserved ejection fraction in women
|